Lyon & Saint-Beauzire, France, October 28th, 2018NEURONAX, the biopharmaceutical company dedicated to develop first-in-class disease-modifying drugs to treat patients with neurodegenerative or traumatic neurological disorders, will present its pre-clinical results highlighting the strong potential of its lead product NX210 during SfN‘s 48th annual meeting, Neuroscience 2018, the world’s largest neuroscience conference for scientists and physicians devoted to understanding the brain and nervous system. The congress will be held in San Diego, USA, from the 3rd to the 7th of November 2018.

 

 

The Society for Neuroscience is the world’s largest organization of scientists and physicians devoted to understanding the brain and nervous system. The nonprofit organization, founded in 1969, now has nearly 36,000 members in more than 95 countries and more than 150 chapters worldwide.

SfN’s annual budget exceeds $30 million and reserves total more than $76 million. Approximately 107 staff are employed at its headquarters building in downtown Washington, DC, which SfN has owned since 2006. Its annual meeting regularly attracts more than 30,000 attendees, representing 80 countries, 536 exhibiting companies, and close to 300 journalists.

 

 

 

Forum 2018 – Poster schedule:

 

Abstract Control Number: 6747

ABSTRACT TITLE: “Neurotrophic, anti-apoptotic and neuroprotective multifunctional activities of NX210, a thrombospondin repeat derived peptide”

 

Session Number: 210

Session Title: Neurotoxicity, Inflammation, and Neuroprotective Mechanisms: Preclinical

Date and Time: Sunday Nov 4, 2018 1:00 PM – 5:00 PM

Location: San Diego Convention Center: SDCC Halls B-H